Proxima (formerly VantAI) is advancing an AI-native approach to drug discovery by making protein interactions programmable. Our platform brings together foundation-model machine learning, a scalable data generation engine, and a partnership track record exceeding $5B in collaborations across the world’s leading biopharma and tech organizations. We’ve recently closed an oversubscribed seed round partnering us with an elite group of sophisticated and dedicated VCs including DCVC, Nvidia’s Nventures, AIX, Yosemite among others.
Neo-1 is our all-atom foundation model that combines state-of-the-art structure prediction and molecular generation in a single system. Neo-1 enables rapid exploration of chemical and structural space for high value, previously intractable targets, and in particular unlocks small molecule proximity therapeutics like molecular glues with AI for the first time.
In parallel, we are developing an advanced structural interactomics platform built on proprietary XLMS technology and a lab equipped with next-generation mass spectrometry instrumentation. This platform produces proteome-scale maps of protein interactions and helps identify small molecules that modulate proximity. Together with Neo-1, it creates an integrated system capable of co-folding protein complexes while generating candidate small molecules to influence those interactions.
Proximity-based therapeutics represent one of most promising frontiers in modern drug discovery with the potential to treat previously intractable diseases and target ‘undruggable’ proteins. Our technology combines proteome-scale structural data with state-of-the-art generative AI foundation models, and coupled with our talented team of scientists and engineers we are uniquely well-positioned to discover and develop a new class of medicines. Come join us!
The Head of Biology will own Proxima's in vitro discovery biology capabilities, from target validation through clinical candidate characterization. You combine deep expertise in biology with hands-on experience in targeted protein degradation. You build assays, lead programs, and connect experimental biology to computational and chemistry teams to advance proximity-based therapeutics.
Lead target identification, validation, and biology support for discovery programs from hit ID to clinical candidate
Build and scale in vitro and ex vivo assay platforms for proximity modulators (degraders, molecular glues, PROTACs)
Design and implement TPD-specific assays including ternary complex, degradation kinetics, and selectivity profiling
Drive cross-functional collaboration between biology, chemistry, ML/computational, and data science teams
Manage external academic and CRO partnerships to extend platform capabilities
PhD in chemical biology, molecular biology, or related discipline
10+ years industry experience in drug discovery biology, including leadership roles
Direct experience with small molecules
Track record advancing programs from discovery to clinical candidate stage
Experience building and leading teams of PhD-level scientists
Direct experience with targeted protein degradation or proximity-inducing modalities
Experience with proteomics-based target ID (chemoproteomic methods, mass spec workflows)
Familiarity with phenotypic screening and mechanism of action elucidation
Exposure to AI/ML-enabled drug discovery or computational-experimental integration
Background spanning multiple modalities (small molecules, degraders, biologics)
Prior work in I&I, cardiometabolic, or oncology therapeutic areas
Highly competitive salaries
Company Equity Package, everyone is a stakeholder!
401(k) + Company Match
Medical, Dental, & Vision Insurance (PPO w/ HSA & FSA options)
13 Paid Holidays + Unlimited PTO & Sick Time
Maternity leave 18 Weeks of fully paid leave + 6 weeks for Paternity leave
In-Office Lunch (5 days per week)
*for US based FTEs, country specific benefits apply for locations outside US